Subscribe To

Price Alert Latest News Economic Calendar News

RMD / ResMed Inc. (RMD) CEO Mick Farrell on Q3 2022 Results - Earnings Call Transcript

ResMed Inc. (NYSE:RMD ) Q3 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President and COO Jim Hollingshead - President, Sleep & Respiratory Care business David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants David Low - JPMorgan Gretel Janu - Credit Suisse Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Dan Hurren - MST Matthew Mishan - KeyBanc David Bailey - Macquarie Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Hello and welcome to the Q3 Fiscal Year 2022 ResMed Earnings Conference Call. My name is Kevin and I'll be your operator for today's call. Read More

Demo Live Account See Partner Details

Content Topics

Resmed

Inc

RMD

Mick

Farrell

2022

Results

Earnings

Call

Transcript

Stock

Posted: Apr 28 2022, 23:15

Author Name: Seeking Alpha

RMD News

By Zacks Investment Research
October 27, 2023

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust

By Seeking Alpha
October 26, 2023

ResMed Inc. (RMD) Q1 2024 Earnings Call Transcript

ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Invest

By Zacks Investment Research
October 26, 2023

ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth consid

By Zacks Investment Research
October 9, 2023

ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.

By Zacks Investment Research
October 3, 2023

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.

By Zacks Investment Research
September 28, 2023

ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the st

By Seeking Alpha
September 12, 2023

ResMed - Trading Opportunity Now

ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from i

By The Motley Fool
September 1, 2023

3 Reasons ResMed's CEO Isn't Worried About Ozempic or Wegovy

Some investors in ResMed, which makes machines for people with sleep apnea, think that effective new weight-loss drugs could shrink its addressable ma

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.